Balyasny Asset Management LLC Celldex Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $58 Billion
- Q3 2024
A detailed history of Balyasny Asset Management LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 86,573 shares of CLDX stock, worth $2.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
86,573Holding current value
$2.32 Million% of portfolio
0.01%Shares
7 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$247 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$126 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$104 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$92.6 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$89.2 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.25B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...